|
|
|
| Bringing 400+ mRNA experts to Boston this July, the 4th mRNA-Based Therapeutics Summit returns to share exclusive scientific and strategic insights spanning the end-to-end of mRNA drug development. Select your sessions from 4 tracks of content dedicated to Discovery, Translation, Clinical Development or CMC, and join the Next Generation mRNA Delivery Day or Regulatory Affairs Strategy Day to maximize your learnings. See the program. |
|
|
|
|
By Elaine Peters, Genentech | Given the mRNA-based products' variability and unique challenges, you may need to modify the standard comparability approach. Let’s discuss strategies for any development stage. |
|
|
|
By Rajendran (Raj) Arunagiri | On Feb. 6, 2024, new legislation was introduced in the House of Representatives: the FDA Modernization Act 3.0. It aims to reduce and replace the use of animals in nonclinical research, improve predictivity of nonclinical testing, and potentially reduce drug development times. This article shares an overview of this proposed legislation. |
|
|
|
Explore the broad benefits and challenges that could be encountered by working with self-amplifying and circular RNA modalities — particularly in terms of manufacturing, raw material supply, COGS, and patient centricity. |
|
|
|
|
|
|
|
|
|
.png){kind=logo}
